Anaptysbio (ANAB) revenue and earnings history
Anaptysbio reported revenue of $235M for fiscal 2025 (year ended Dec 31, 2025), +157.0% on the year before, and net income of −$13.2M.
Over 10 years, from fiscal 2015 to fiscal 2025, revenue grew at a compound rate of +29.6% a year.
Revenue and net income, 11 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $235M+157.0% | $47.9M | −$13.2M | $19.7M | $87K | $19.6M | $36.1M | $68.6M | — | $238M | — | 10-K/A |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Anaptysbio (ANAB) on OQRO.
Common questions
What was Anaptysbio's revenue in fiscal 2025?
$235M for the year ended Dec 31, 2025, as reported in its 10-K/A filed Apr 28, 2026. That is +157.0% on fiscal 2024 ($91.3M).
How fast has Anaptysbio's revenue grown?
From $17.6M in fiscal 2015 to $235M in fiscal 2025: a compound annual growth rate of +29.6% over 10 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Anaptysbio tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
